Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
ACADEMIA
Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
Nobel Prize winner Tasuku Honjo on June 19 filed a lawsuit against Ono Pharmaceutical with the Osaka District Court, demanding some 22.6 billion yen from the drug maker over patent royalties pertaining to the anti-PD-1 antibody Opdivo (nivolumab). According to…
To read the full story
Related Article
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Ono Offers Its Account of License Fee Row with Nobel Laureate
May 23, 2019
- I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
October 2, 2018
ACADEMIA
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Tohoku University Trial Finds Kidney Benefits for Constipation Drug Lubiprostone
September 3, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…